COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series
- PMID: 32570202
- PMCID: PMC7228884
- DOI: 10.1016/j.msard.2020.102192
COVID-19 in persons with multiple sclerosis treated with ocrelizumab - A pharmacovigilance case series
Conflict of interest statement
Declaration of Competing Interest Drs Hughes, Pedotti, and Koendgen are employees of F. Hoffmann-La Roche Ltd. There was no funding to this research.
Comment on
-
COVID-19 in a MS patient treated with ocrelizumab: does immunosuppression have a protective role?Mult Scler Relat Disord. 2020 Jul;42:102120. doi: 10.1016/j.msard.2020.102120. Epub 2020 Apr 15. Mult Scler Relat Disord. 2020. PMID: 32315980 Free PMC article.
References
-
- European Medicines Agency, 2017. Guideline on good pharmacovigilance practices (GVP) – Module VI (Rev 2) EMA/873138/2011 Rev 2. https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/g... (accessed 5 May 2020).
-
- European Medicines Agency, 1995. ICH Harmonised Tripartite Guideline E2A. https://www.ema.europa.eu/en/documents/scientific-guideline/internationa... (accessed 5 May 2020).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical